Given the widespread use of GLP‐1 agents and ongoing safety concerns, future research needs to study these drugs in breast cancer patients, critically evaluating their impact on cancer risk, recurrence, mortality, and long‐term outcomes for this population. Here, GLP1R is linked to breast cancer.